Antibodies Directed Against ICOS and Uses Thereof
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Universite D'Aix-Marseille, Universite Claude Bernard Lyon 1, Centre Leon Berard
InventorsJulien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
Claims9
1-9. (canceled)
A method of treating cancer in a human in need thereof, the method comprising administering to the human an anti-ICOS antibody or antigen binding portion thereof that binds human ICOS, wherein the anti-ICOS antibody or antigen binding portion thereof comprises a CDRH3 comprising a conservative amino acid substitution in the sequence set forth in SEQ ID NO:
- 9,
- wherein the conservative amino acid substitution is tyrosine to serine.
Dependencies are inferred from the claim text.